Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Differential expression of the alternatively spliced forms of prosaposin mRNAs in rat choroid plexus

  • 261 Accesses

  • 5 Citations

Abstract

Prosaposin has two distinct profiles. One is a precursor form that is processed into saposins thus promoting lysosomal sphingolipid hydrolase function, whereas the other is an intact form that is not processed into saposins but is abundant in certain tissues and secretory fluids, including the cerebrospinal fluid. In rats, alternative splicing in the prosaposin gene generates mRNAs with and without a 9-base insertion (Pro+9 and Pro+0 mRNAs, respectively). Pro+9 mRNA is reported to be preferentially expressed in tissues in which the intact form of prosaposin dominates, whereas Pro+0 mRNA is preferentially expressed in tissues in which the precursor dominates. The expression patterns of Pro+9 and Pro+0 mRNAs in the rat choroid plexus are examined in the present study. The specificities of 36-mer oligonucleotide probes used to detect the 9-base insertion by in situ hybridization were demonstrated by dot-blot hybridization. Next, these probes were used for in situ hybridization, which showed predominant expression of Pro+0 mRNA and weak expression of Pro+9 mRNA in the choroid plexus. These expression patterns were confirmed by reverse transcription plus the polymerase chain reaction with AlwI restriction enzyme treatment. Expression of the intact form of prosaposin in the choroid plexus was assessed by Western blotting and immunohistochemistry. Because the choroid plexus is responsible for the generation of cerebrospinal fluid containing the intact form of prosaposin, the present study raises the possibility that Pro+0 mRNA is related to the intact form in the choroid plexus and that the alternatively spliced forms of mRNAs do not simply correspond to the precursor and intact forms of prosaposin.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Borlongan CV, Skinner SJ, Geaney M, Vasconcellos AV, Elliott RB, Emerich DF (2004) Intracerebral transplantation of porcine choroid plexus provides structural and functional neuroprotection in a rodent model of stroke. Stroke 35:2206–2210

  2. Campana WM, Hiraiwa M, O’Brien JS (1998) Prosaptide activates the MAPK pathway by a G-protein-dependent mechanism essential for enhanced sulfatide synthesis by Schwann cells. FASEB J 12:307–314

  3. Chen J, Saito S, Kobayashi N, Sato K, Terashita T, Shimokawa T, Mominoki K, Miyawaki K, Sano A, Matsuda S (2008) Expression patterns in alternative splicing forms of prosaposin mRNA in the rat facial nerve nucleus after facial nerve transection. Neurosci Res 60:82–94

  4. Cleveland DW, Fischer SG, Kirschner MW, Laemmli UK (1977) Peptide mapping by limited proteolysis in sodium dodecyl sulfate and analysis by gel electrophoresis. J Biol Chem 252:1102–1106

  5. Cohen T, Ravid L, Altman N, Madar-Shapiro L, Fein A, Weil M, Horowitz M (2004) Conservation of expression and alternative splicing in the prosaposin gene. Mol Brain Res 129:8–19

  6. Cohen T, Auerbach W, Ravid L, Bodennec J, Fein A, Futerman AH, Joyner AL, Horowitz M (2005) The exon 8-containing prosaposin gene splice variant is dispensable for mouse development, lysosomal function, and secretion. Mol Cell Biol 25:2431–2440

  7. Fawcett DW (1986) Bloom and Fawcett, a text book of histology, 11th edn. Saunders, Philadelphia

  8. Gao HL, Li C, Nabeka H, Shimokawa T, Saito S, Wang ZY, Cao YM, Matsuda S (2013) Attenuation of MPTP/MPP(+) toxicity in vivo and in vitro by an 18-mer peptide derived from prosaposin. Neuroscience 236:373–393

  9. Harzer K, Paton BC, Christomanou H, Chatelut M, Levade T, Hiraiwa M, O’Brien JS (1997) Saposins (sap) A and C activate the degradation of galactosylceramide in living cells. FEBS Lett 417:270–274

  10. Harzer K, Hiraiwa M, Paton BC (2001) Saposins (sap) A and C activate the degradation of galactosylsphingosine. FEBS Lett 508:107–110

  11. Henseler M, Klein A, Glombitza GJ, Suziki K, Sandhoff K (1996) Expression of the three alternative forms of the sphingolipid activator protein precursor in baby hamster kidney cells and functional assays in a cell culture system. J Biol Chem 271:8416–8423

  12. Hineno T, Sano A, Kondoh K, Ueno S, Kakimoto Y, Yoshida K (1991) Secretion of sphingolipid hydrolase activator precursor, prosaposin. Biochem Biophys Res Commun 176:668–674

  13. Hiraiwa M, O’Brien JS, Kishimoto Y, Galdzicka M, Fluharty AL, Ginns EI, Martin BM (1993) Isolation, characterization, and proteolysis of human prosaposin, the precursor of saposins (sphingolipid activator proteins). Arch Biochem Biophys 304:110–116

  14. Hiraiwa M, Campana WM, Martin BM, O’Brien JS (1997a) Prosaposin receptor: evidence for a G-protein-associated receptor. Biochem Biophys Res Commun 240:415–418

  15. Hiraiwa M, Martin BM, Kishimoto Y, Conner GE, Tsuji S, O’Brien JS (1997b) Lysosomal proteolysis of prosaposin, the precursor of saposins (sphingolipid activator proteins): its mechanism and inhibition by ganglioside. Arch Biochem Biophys 341:17–24

  16. Hiraiwa M, Taylor EM, Campana WM, Darin SJ, O’Brien JS (1997c) Cell death prevention, mitogen-activated protein kinase stimulation, and increased sulfatide concentrations in Schwann cells and oligodendrocytes by prosaposin and prosaptides. Proc Natl Acad Sci U S A 94:4778–4781

  17. Hiraiwa M, Campana WM, Mizisin AP, Mohiuddin L, O’Brien JS (1999) Prosaposin: a myelinotrophic protein that promotes expression of myelin constituents and is secreted after nerve injury. Glia 26:353–360

  18. Hiraiwa M, Liu J, Lu AG, Wang CY, Misasi R, Yamauchi T, Hozumi I, Inuzuka T, O’Brien JS (2003) Regulation of gene expression in response to brain injury: enhanced expression and alternative splicing of rat prosaposin (SGP-1) mRNA in injured brain. J Neurotrauma 20:755–765

  19. Holtschmidt H, Sandhoff K, Furst W, Kwon HY, Schnabel D, Suzuki K (1991a) The organization of the gene for the human cerebroside sulfate activator protein. FEBS Lett 280:267–270

  20. Holtschmidt H, Sandhoff K, Kwon HY, Harzer K, Nakano T, Suzuki K (1991b) Sulfatide activator protein. Alternative splicing that generates three mRNAs and a newly found mutation responsible for a clinical disease. J Biol Chem 266:7556–7560

  21. Hosoda Y, Miyawaki K, Saito S, Chen J, Bing X, Terashita T, Kobayashi N, Araki N, Shimokawa T, Hamada F, Sano A, Tanabe H, Matsuda S (2007) Distribution of prosaposin in the rat nervous system. Cell Tissue Res 330:197–207

  22. Kishimoto Y, Hiraiwa M, O’Brien JS (1992) Saposins: structure, function, distribution, and molecular genetics. J Lipid Res 33:1255–1267

  23. Klein A, Henseler M, Klein C, Suzuki K, Harzer K, Sandhoff K (1994) Sphingolipid activator protein D (sap-D) stimulates the lysosomal degradation of ceramide in vivo. Biochem Biophys Res Commun 200:1440–1448

  24. Kondoh K, Sano A, Kakimoto Y, Matsuda S, Sakanaka M (1993) Distribution of prosaposin-like immunoreactivity in rat brain. J Comp Neurol 334:590–602

  25. Koochekpour S, Hu S, Vellasco-Gonzalez C, Bernardo R, Azabdaftari G, Dalin G, Zhau HE, Chung LW, Vessella RL (2012) Serum prosaposin levels are increased in patients with advanced prostate cancer. Prostate 72:253–269

  26. Kotani Y, Matsuda S, Sakanaka M, Kondoh K, Ueno S, Sano A (1996a) Prosaposin facilitates sciatic nerve regeneration in vivo. J Neurochem 66:2019–2025

  27. Kotani Y, Matsuda S, Wen TC, Sakanaka M, Tanaka J, Maeda N, Kondoh K, Ueno S, Sano A (1996b) A hydrophilic peptide comprising 18 amino acid residues of the prosaposin sequence has neurotrophic activity in vitro and in vivo. J Neurochem 66:2197–2200

  28. Lamontagne S, Potier M (1994) Modulation of human saposin B sphingolipid-binding specificity by alternative splicing. A study with saposin B-derived synthetic peptides. J Biol Chem 269:20528–20532

  29. Leonova T, Qi X, Bencosme A, Ponce E, Sun Y, Grabowski GA (1996) Proteolytic processing patterns of prosaposin in insect and mammalian cells. J Biol Chem 271:17312–17320

  30. Li SC, Kihara H, Serizawa S, Li YT, Fluharty AL, Mayes JS, Shapiro LJ (1985) Activator protein required for the enzymatic hydrolysis of cerebroside sulfate. J Biol Chem 260:1867–1871

  31. Li N, Sarojini H, An J, Wang E (2010) Prosaposin in the secretome of marrow stroma-derived neural progenitor cells protects neural cells from apoptotic death. J Neurochem 112:1527–1538

  32. Li C, Gao HL, Shimokawa T, Nabeka H, Hamada F, Araki H, Cao YM, Kobayashi N, Matsuda S (2013) Prosaposin expression in the regenerated muscles of mdx and cardiotoxin-treated mice. Histol Histopathol 28:875–892

  33. Madar-Shapiro L, Pasmanik-Chor M, Vaccaro AM, Dinur T, Dagan A, Gatt S, Horowitz M (1999) Importance of splicing for prosaposin sorting. Biochem J 337:433–443

  34. Meyer RC, Giddens MM, Schaefer SA, Hall RA (2013) GPR37 and GPR37L1 are receptors for the neuroprotective and glioprotective factors prosaptide and prosaposin. Proc Natl Acad Sci U S A 110:9529–9534

  35. Mocchetti I (2005) Exogenous gangliosides, neuronal plasticity and repair, and the neurotrophins. Cell Mol Life Sci 62:2283–2294

  36. Nakano T, Sandhoff K, Stumper J, Christomanou H, Suzuki K (1989) Structure of full-length cDNA coding for sulfatide activator, a Co-beta-glucosidase and two other homologous proteins: two alternate forms of the sulfatide activator. J Biochem 105:152–154

  37. O’Brien JS, Kishimoto Y (1991) Saposin proteins: structure, function, and role in human lysosomal storage disorders. FASEB J 5:301–308

  38. O’Brien JS, Kretz KA, Dewji N, Wenger DA, Esch F, Fluharty AL (1988) Coding of two sphingolipid activator proteins (SAP-1 and SAP-2) by same genetic locus. Science 241:1098–1101

  39. O’Brien JS, Carson GS, Seo HC, Hiraiwa M, Kishimoto Y (1994) Identification of prosaposin as a neurotrophic factor. Proc Natl Acad Sci U S A 91:9593–9596

  40. O’Brien JS, Carson GS, Seo HC, Hiraiwa M, Weiler S, Tomich JM, Barranger JA, Kahn M, Azuma N, Kishimoto Y (1995) Identification of the neurotrophic factor sequence of prosaposin. FASEB J 9:681–685

  41. Salvioli R, Ricci-Vitiani L, Tatti M, Scarpa S, De Maria R, Vaccaro AM (2008) The secretion and maturation of prosaposin and procathepsin D are blocked in embryonic neural progenitor cells. Biochim Biophys Acta 1783:1480–1489

  42. Sano A, Hineno T, Mizuno T, Kondoh K, Ueno S, Kakimoto Y, Inui K (1989) Sphingolipid hydrolase activator proteins and their precursors. Biochem Biophys Res Commun 165:1191–1197

  43. Sano A, Matsuda S, Wen TC, Kotani Y, Kondoh K, Ueno S, Kakimoto Y, Yoshimura H, Sakanaka M (1994) Protection by prosaposin against ischemia-induced learning disability and neuronal loss. Biochem Biophys Res Commun 204:994–1000

  44. Schulze H, Kolter T, Sandhoff K (2009) Principles of lysosomal membrane degradation: cellular topology and biochemistry of lysosomal lipid degradation. Biochim Biophys Acta 1793:674–683

  45. Shimokawa T, Nabeka H, Yamamiya K, Wakisaka H, Takeuchi T, Kobayashi N, Matsuda S (2013) Distribution of prosaposin in rat lymphatic tissues. Cell Tissue Res 352:685–693

  46. Sun Y, Witte DP, Grabowski GA (1994) Developmental and tissue-specific expression of prosaposin mRNA in murine tissues. Am J Pathol 145:1390–1398

  47. Terashita T, Saito S, Nabeka H, Hato N, Wakisaka H, Shimokawa T, Kobayashi N, Gyo K, Matsuda S (2012) Prosaposin-derived peptide alleviates ischaemia-induced hearing loss. Acta Otolaryngol 133:462–468

  48. Tsuboi K, Hiraiwa M, O’Brien JS (1998) Prosaposin prevents programmed cell death of rat cerebella granule neurons in culture. Dev Brain Res 110:249–255

  49. Wessel D, Flügge UI (1984) A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem 138:141–143

  50. Winau F, Schwierzeck V, Hurwitz R, Remmel N, Sieling PA, Modlin RL, Porcelli SA, Brinkmann V, Sugita M, Sandhoff K, Kaufmann SH, Schaible UE (2004) Saposin C is required for lipid presentation by human CD1b. Nat Immunol 5:169–174

  51. Xue B, Chen J, Gao H, Saito S, Kobayashi N, Shimokawa T, Nabeka H, Sano A, Matsuda S (2011) Chronological changes in prosaposin in the developing rat brain. Neurosci Res 71:22–34

  52. Yuan W, Qi X, Tsang P, Kang SJ, Illarionov PA, Besra GS, Gumperz J, Cresswell P (2007) Saposin B is the dominant saposin that facilitates lipid binding to human CD1d molecules. Proc Natl Acad Sci U S A 104:5551–5556

  53. Zappaterra MW, Lehtinen MK (2012) The cerebrospinal fluid: regulator of neurogenesis, behavior, and beyond. Cell Mol Life Sci 69:2863–2878

  54. Zhao Q, Bell AW, El-Alfy M, Morales CR (1998) Mouse testicular sulfated glycoprotein-1: sequence analysis of the common backbone structure of prosaposins. J Androl 19:165–174

Download references

Acknowledgments

This study was supported in part by a grant to S.S. (No. 23580401) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

Author information

Correspondence to Shouichiro Saito.

Additional information

The English in this document has been checked by at least two professional editors, both native speakers of English (for a certificate, see http://www.textcheck.com/certificate/ect0Cr).

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Saito, S., Saito, K., Nabeka, H. et al. Differential expression of the alternatively spliced forms of prosaposin mRNAs in rat choroid plexus. Cell Tissue Res 356, 231–242 (2014). https://doi.org/10.1007/s00441-013-1773-9

Download citation

Keywords

  • Choroid plexus
  • Prosaposin secretion
  • Neurotrophic factor
  • Hippocampus
  • Saposin B
  • Rat (Wistar, male)